U.S. Stem Cell, Inc.
USRM
$0.0001
$0.000.00%
| 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -15.25% | -75.22% | -30.79% | -72.39% | -79.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.25% | -75.22% | -30.79% | -72.39% | -79.53% |
| Cost of Revenue | -43.02% | -62.68% | -54.74% | -52.90% | -18.87% |
| Gross Profit | 0.67% | -79.12% | -16.06% | -76.78% | -85.67% |
| SG&A Expenses | 3.10% | -25.99% | -43.55% | -4.57% | -30.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.07% | -26.93% | -43.72% | -5.88% | -30.48% |
| Operating Income | -3.17% | 21.43% | 44.32% | -5.62% | 17.61% |
| Income Before Tax | 11.61% | 15.91% | 42.66% | -17.96% | -8.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.61% | 15.91% | 42.66% | -17.96% | -8.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.61% | 15.91% | 42.66% | -17.96% | -8.70% |
| EBIT | -3.17% | 21.43% | 44.32% | -5.62% | 17.61% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 30.77% | 40.00% | 54.55% | 0.00% | 7.14% |
| Normalized Basic EPS | 45.45% | 33.33% | 53.85% | 11.11% | -37.50% |
| EPS Diluted | 30.77% | 40.00% | 54.55% | 0.00% | 7.14% |
| Normalized Diluted EPS | 45.45% | 33.33% | 53.85% | 11.11% | -37.50% |
| Average Basic Shares Outstanding | 29.27% | 33.81% | 32.23% | 17.73% | 12.75% |
| Average Diluted Shares Outstanding | 29.27% | 33.81% | 32.23% | 17.73% | 12.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
